Baseline Physiology Studies in Carriers of Gene Variant X Conferring Major Risk of CVD-prone Metabolic Disorders
This study has been completed.
University of Aarhus
First Posted: April 5, 2012
Last Update Posted: December 2, 2014
Aarhus University Hospital
Steno Diabetes Center
University of Copenhagen
Information provided by (Responsible Party):
Julie Støy, University of Aarhus
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||November 2014|
|Primary Completion Date:||July 2013 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Støy J, Kampmann U, Mengel A, Magnusson NE, Jessen N, Grarup N, Rungby J, Stødkilde-Jørgensen H, Brandslund I, Christensen C, Hansen T, Pedersen O, Møller N. Reduced CD300LG mRNA tissue expression, increased intramyocellular lipid content and impaired glucose metabolism in healthy male carriers of Arg82Cys in CD300LG: a novel genometabolic cross-link between CD300LG and common metabolic phenotypes. BMJ Open Diabetes Res Care. 2015 Aug 26;3(1):e000095. doi: 10.1136/bmjdrc-2015-000095. eCollection 2015.